









Markets
/
Stocks
/
nasdaq-tcrt
/

Alaunos Therapeutics Inc

TCRT

2.520USD

-0.190-7.01%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

5.23MMarket Cap

LossP/E TTM



Alaunos Therapeutics Inc

2.520

-0.190-7.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alaunos Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alaunos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

235 / 407

Overall Ranking

468 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alaunos Therapeutics Inc Highlights

StrengthsRisks

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.00K.

Overvalued

The company’s latest PE is 0.19, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 104.77K shares, decreasing 59.26% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 23.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.64.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.73, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 6.91%.

Score

Industry at a Glance

Previous score

6.73

Change



Financials

5.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.60

Key Metrics

Free cash flow

No Data

Alaunos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.54, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 0.19, which is 102.79% below the recent high of 0.38 and 2562.68% above the recent low of -4.67.

Score

Industry at a Glance

Previous score

7.54

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 235/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 3.94, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 3.90 and the support level at 1.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.02

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.122

Neutral

RSI(14)

42.455

Neutral

STOCH(KDJ)(9,3,3)

20.955

Sell

ATR(14)

0.189

Low Volatility

CCI(14)

-104.097

Sell

Williams %R

98.684

Oversold

TRIX(12,20)

-0.120

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.670

Sell

MA10

2.702

Sell

MA20

3.005

Sell

MA50

2.628

Sell

MA100

3.029

Sell

MA200

2.603

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 4.77%, representing a quarter-over-quarter decrease of 63.55%. The largest institutional shareholder is The Vanguard, holding a total of 20.97K shares, representing 0.96% of shares outstanding, with 27.04% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Vieser (Jaime W.)

33.33K

+11.36%

Watermill Asset Management

33.33K

Postma (Robert W.)

33.15K

+13.92%

BlackRock Institutional Trust Company, N.A.

21.35K

The Vanguard Group, Inc.

Star Investors

20.97K

Geode Capital Management, L.L.C.

15.95K

+2.15%

Groenewald (Ferdinand)

10.78K

UBS Financial Services, Inc.

5.58K

-15.90%

Hogue (Dale Curtis Jr.)

4.44K

+11.05%

Morgan Stanley Smith Barney LLC

1.74K

+133.51%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.58, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -1.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.